Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10046758 | 0.92 | USP2 (0.37) | MAPTMAPK1NPSR1USP2LMNA | |
| SCHEMBL14213246 | 0.83 | KDM4E (0.40) | MAPTMAPK1NPSR1USP2LMNA | |
| SCHEMBL14213254 | 0.77 | LMNA (0.39) | MAPTMAPK1NPSR1USP2LMNA | |
| SCHEMBL14680975 | 0.76 | KDM4E (0.43) | MAPTMAPK1NPSR1USP2LMNA | |
| SCHEMBL14681024 | 0.76 | SLC1A5 (0.40) | MAPTMAPK1NPSR1USP2LMNA | |
| SCHEMBL14213265 | 0.73 | CYP2C19 (0.35) | HSD17B10SMN1; SMN2 | |
| SCHEMBL799826 | 0.72 | MAPT (0.43) | MAPTMAPK1NPSR1KDM4EGAA | |
| SCHEMBL19499040 | 0.72 | USP2 (0.47) | MAPTMAPK1NPSR1USP2LMNA | |
| SCHEMBL10046742 | 0.72 | ESR1 (0.46) | MAPK1NPSR1USP2LMNACYP3A4 | |
| SCHEMBL10046756 | 0.70 | KDM4E (0.40) | USP2LMNACYP3A4HSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716343-B2 | Calixarene-based peptide conformation mimetics, methods of use, and methods of making | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2014-05-06 | — | — | US | disclosed |
| US-8642656-B2 | Calixarene-based peptide conformation mimetics, methods of use, and methods of making | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130035394-A1 | Calixarene-Based Peptide Conformation Mimetics, Methods of Use, and Methods of Making | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2013-02-07 | — | — | US | disclosed |
| US-20120309801-A1 | CALIXARENE-BASED PEPTIDE CONFORMATION MIMETICS, METHODS OF USE, AND METHODS OF MAKING | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2012-12-06 | — | — | US | disclosed |
| US-8207228-B2 | Calixarene-based peptide conformation mimetics, methods of use, and methods of making | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2012-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035394-A1 | Calixarene-Based Peptide Conformation Mimetics, Methods of Use, and Methods of Making | CLSPN, BID, CALU | MAPT 4561/4885MAPK1 4266/4885NPSR1 1564/4885 |
| US-20120309801-A1 | CALIXARENE-BASED PEPTIDE CONFORMATION MIMETICS, METHODS OF USE, AND METHODS OF MAKING | CLSPN, BID, CALU | MAPT 4561/4885MAPK1 4266/4885NPSR1 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.